Drug Profile

T cell engager therapeutic - Wuxi Biologics

Alternative Names: CD 19 targeting T cell engager therapeutics - Candid Therapeutics; Trispecific T cell engager therapeutic - Wuxi Biologics

Latest Information Update: 10 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator WuXi Biologics
Developer Candid Therapeutics; WuXi Biologics
Class Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins; Trispecific antibodies
Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

06 Jan 2025 Candid Therapeutics in-licenses T cell engager therapeutic from WuXi Biologics
06 Jan 2025 Candid Therapeutics plans first-in-human studies in the first half of 2026
06 Jan 2025 Preclinical trials in Autoimmune disorders in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com